Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

This study has been completed.
Sponsor:
Information provided by:
Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier:
NCT00939835
First received: July 13, 2009
Last updated: July 15, 2009
Last verified: July 2009
  Purpose
  • Objective:

    • The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Limited) to the Reference Product, RLD Tablets 40 mg (Forest Pharmaceuticals Inc, Missouri) under fed condition
  • Study Design:

    • Randomized, Single Dose, Open Label, Non-Replicate, Two-period, Two-treatment, Two- Sequence Crossover Bioequivalence Study comparing Citalopram Hydrobromide Tablets 40 mg (manufactured by Torrent Pharmaceuticals Ltd). With RLD Tablets 40 mg (manufactured by Forest Pharmaceuticals Inc Missouri) in 24+2 normal healthy male subjects with a wash out period of 15 days between the two study periods, in fed condition.

Condition Intervention Phase
Healthy
Drug: Citalopram Hydrobromide
Phase 1

Study Type: Interventional
Official Title: A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

Resource links provided by NLM:


Further study details as provided by Torrent Pharmaceuticals Limited:

Primary Outcome Measures:
  • Bioequivalence

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Male and female subjects in the range of 18 - 45 years of age.
  • Body weight within ± 15% of the weight range as related to height, as per the Life Insurance Corporation (LIC) Chart. (Appendix A)
  • No abnormal findings as determined by baseline history, physical examination, vital signs (blood pressure, pulse rate, respiration rate and body temperature) hematological tests, serum chemistry, urinalysis, ECG and Chest X-ray.
  • Subjects having values above/below the reference range, (Appendix J) for hematological, serum chemistry and urine analysis values will be clinically correlated for signs and symptoms. These subjects will be included if found asymptomatic.
  • Willingness to follow, the protocol requirements, as evidenced by written, informed consent.
  • Agreeing to, not to use any medication (prescription and over the counter), including vitamins and minerals for 15 days prior to study & during the course of the study.
  • No history or presence of significant alcoholism or drug abuse in the past one year.
  • Subjects should preferably be non-smokers. If moderate smokers are included (less than 10 cigarette per day) as per guidelines will be identified as such and documented in the history taking form in CRF.

Exclusion Criteria:

  • Requiring medication for any ailment.
  • Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
  • History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic or psychiatric diseases.
  • Participation in a clinical drug study or Bioequivalence study 90 days prior to present study.
  • History of malignancy or other serious diseases.
  • Refusal to abstain from food for ten (10) hours prior to study drug administration on first day of each study period and for four (4) additional hours each, post dose.
  • Refusal to abstain from water for one (1) hour prior to study drug administration on first day of each study period and for one (1) additional hour, post dosing.
  • Any contraindication to blood sampling.
  • Smoking or consumption of tobacco products during the study.
  • Use of xanthine-containing beverages or food for 48 hours prior to each drug dose.
  • Blood donation 30 days prior to the commencement of the study.
  • Subjects with positive HIV tests.
  • Subjects with positive HbsAg or Hepatitis-C tests.
  • Known history of hypersensitivity Citalopram or related drugs.
  • Pregnant and lactating women.
  • At the time of screening, prior to enrollment, presence of pregnancy will be confirmed by urine pregnancy test.
  • Just prior to commencement of study (for both periods), presence of pregnancy will be confirmed by urine pregnancy test.
  • Female subjects not confirm to using birth control measures, from the date of screening till the completion of the second period of the study. Abstinence, barrier methods (condom, diaphragm, etc.) are acceptable. Use of hormonal contraceptives either oral or implants will not be acceptable.
  • Female subjects whose menstruation cycle coincides with the study periods.
  • History of drug abuse in the past one year.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00939835

Locations
India
Accutest Research Laboratories Pvt. Ltd.
Mumbai, Maharashtra, India, 400 709
Sponsors and Collaborators
Torrent Pharmaceuticals Limited
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00939835     History of Changes
Other Study ID Numbers: US/05/002
Study First Received: July 13, 2009
Last Updated: July 15, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Citalopram
Dexetimide
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014